Literature DB >> 9714427

Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation.

A W Wright1, M L Nocente, M T Smith.   

Abstract

Hydromorphone-3-glucuronide (H3G) was synthesized biochemically using rat liver microsomes, uridine-5'-diphosphoglucuronic acid (UDPGA) and the substrate, hydromorphone. Initially, the crude putative H3G product was purified by ethyl acetate precipitation and washing with acetonitrile. Final purification was achieved using semi-preparative high-performance-liquid-chromatography (HPLC) with ultraviolet (UV) detection. The purity of the final H3G product was shown by HPLC with electrochemical and ultraviolet detection to be > 99.9% and it was produced in a yield of = 60% (on a molar basis). The chemical structure of the putative H3G was confirmed by enzymatic hydrolysis of the glucuronide moiety using beta-glucuronidase, producing a hydrolysis product with the same HPLC retention time as the hydromorphone reference standard. Using HPLC with tandem mass spectrometry (HPLC-MS-MS) in the positive ionization mode, the molecular mass (M+1) was found to be 462 g/mol, in agreement with H3G's expected molecular weight of 461 g/mol. Importantly, proton-NMR indicated that the glucuronide moiety was attached at the 3-phenolic position of hydromorphone. A preliminary evaluation of H3G's intrinsic pharmacological effects revealed that following i.c.v. administration to adult male Sprague-Dawley rats in a dose of 5 microg, H3G evoked a range of excitatory behavioural effects including chewing, rearing, myoclonus, ataxia and tonic-clonic convulsions, in a manner similar to that reported previously for the glucuronide metabolites of morphine, morphine-3-glucuronide and normorphine-3-glucuronide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714427     DOI: 10.1016/s0024-3205(98)00288-4

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 2.  Opioid metabolism.

Authors:  Howard S Smith
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

3.  Direct MS-MS identification of isoxsuprine-glucuronide in post-administration equine urine.

Authors:  J M Bosken; A F Lehner; A Hunsucker; J D Harkins; W E Woods; W Karpiesiuk; W G Carter; J Boyles; M Fisher; T Tobin
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

4.  Relationship between plasma concentrations of morphine and its metabolites and pain in cancer patients.

Authors:  Tomoya Sakurada; Shinya Takada; Hisae Eguchi; Keishiro Izumi; Nobunori Satoh; Shiro Ueda
Journal:  Pharm World Sci       Date:  2010-08-21

5.  Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.

Authors:  S S Lewis; M R Hutchinson; N Rezvani; L C Loram; Y Zhang; S F Maier; K C Rice; L R Watkins
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

Review 6.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 7.  Hydromorphone Prescription for Pain in Children-What Place in Clinical Practice?

Authors:  Frédérique Rodieux; Anton Ivanyuk; Marie Besson; Jules Desmeules; Caroline F Samer
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

8.  Predicting drug-metagenome interactions: Variation in the microbial β-glucuronidase level in the human gut metagenomes.

Authors:  Moamen M Elmassry; Sunghwan Kim; Ben Busby
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.